Remove 2025 Remove Drug Development Remove Pharmacy
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs 64
article thumbnail

Pharmacy Considerations for Early Phase Trials

Fierce BioTech

First-in-Human, Drug-Drug Interaction, Food Effect, Bioequivalence, etc.), and often require consistent batches of drug product be administered to groups of research participants within a short timeframe, early phase studies present unique challenges for drug developers not typically experienced in later stages of development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

OTC and Consumer Health Products : Brands in this segment benefit from lean, geographically dispersed sales forces that focus on brand visibility and pharmacy-level engagement. Biosimilars and Generics : Where cost competition necessitates strategic brand differentiation and efficient coverage.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. This study is planned to start in late 2024 and conclude in late 2025.

FDA 40
article thumbnail

Consultant’s Corner—Reflections from a Study Monitor and Director: A Career in Toxicology, by Bill Brock

Alta Sciences

Consultants CornerReflections from a Study Monitor and Director: A Career in Toxicology, by Bill Brock pmjackson Fri, 05/16/2025 - 18:40 Some might say a reflective piece like this could come across as sounding preachy. There, he supports PhD candidates and guides graduate research exploring the mechanisms of drug-induced liver toxicity.

article thumbnail

Analysis Life Sciences Thank You 166 guidance documents the FDA is actively working on in 2024 (and beyond)

Agency IQ

If you’re looking for something specific, we recommend using the search function in your browser (Ctrl-F) to look for keywords of interest.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025. What ever happened to that thing?

FDA 40